Search results for: Generics
Filter search results
OHE Lunchtime Seminar: Price Regulation of Generics and Drug Shortages
21 November 2018
…‘Price Regulation of Generics and Drug Shortages’ to be held on 27th November 2018 from 12 p.m. to 2 p.m. Generic pharmaceutical markets in Canada are subject to various ‘price-cap’ regulations referred to as…
OHE Lunchtime Seminar: Price Regulation of Generics and Drug Shortages
8 November 2018
…‘Price Regulation of Generics and Drug Shortages’ to be held on 27th November 2018 from 12 p.m. to 2 p.m. Generic pharmaceutical markets in Canada are subject to various…
OHE Lunchtime Seminar: Price Regulation of Generics and Drug Shortages
27 November 2018, 12:00am
OHE Lunchtime Seminar with Dr. Aslam Anis, The University of British Columbia, School of Population and Public Health. Generic pharmaceutical markets in Canada are subject to various ‘price-cap’ regulations referred…
Pricing in Emerging Markets: Income, Competition and Procurement
16 August 2011
…and the uncertain quality of generics in many MLICs have a negative impact on competition and make pricing based on PCI difficult at best. Encouraging generics of uncertain quality, moreover,…
Review of CRA’s Report “Assessing the Economic Impacts of Changing Exemption Provisions During Patent and SPC Protection in Europe”
1 January 2018
…on lower value generics where EU global competitiveness appears to be weaker. The CRA Report has an underlying assumption that the EU is as globally competitive in generics and biosimilars…
Biosimilars and Data Exclusivity
8 June 2010
…will be substantially less for biosimilars than for generics because of two factors. On the supply side, development costs for biosimilars are much higher than for generics; on the demand side, uptake…
Can Transparency Lower Prices and Improve Access to Pharmaceuticals? Five Questions We Think Matter a Lot
29 March 2019
…Figure below, two-thirds of the market by value in low and lower middle-income markets included in CGD’s analysis goes to, almost exclusively, branded generics. Further review of data from a…
The Spanish Medicines Market Today
9 February 2011
…May 2010, new price cuts were imposed on all reference priced generics, ranging from 0%-30% depending on the difference between the generic’s current price and the reference price. Exempted are…
Biosimilars: Issues Overview
1 June 2010
…of the characteristics of biologics. Biosimilars are not ‘biogenerics’, that is, the molecules differ and so require regulatory data beyond what is required for generics. This also limits interchangeability, i.e., to…